Expertise in
18
conditions

Dr. Lisa M. Landrum

Gynecologic Oncology | Palliative Medicine | Obstetrics and Gynecology
University Obstetricians-Gynecologists,inc
535 Barnhill Dr, 
Indianapolis, IN 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
18
conditions
University Obstetricians-Gynecologists,inc
535 Barnhill Dr, 
Indianapolis, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lisa Landrum is a Gynecologic Oncologist and a Palliative Medicine provider in Indianapolis, Indiana. Dr. Landrum is highly rated in 18 conditions, according to our data. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Sertoli-Leydig Cell Tumor, Hysterectomy, and Salpingo-Oophorectomy. Dr. Landrum is currently accepting new patients.

Her clinical research consists of co-authoring 58 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Palliative Medicine
Obstetrics and Gynecology
Licenses
Hospice and Palliative Medicine in IN
Hospital Affiliations
Indiana University Health
Indiana University Health Ball Memorial Hospital
Indiana University Health North Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

UNIVERSITY OBSTETRICIANS-GYNECOLOGISTS,INC
535 Barnhill Dr, Indianapolis, IN 46202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase Ib Trial of Vaginal Cuff Brachytherapy + Pembrolizumab (MK3475) Followed by 3 Cycles of Dose Dense Paclitaxel/q 21 Day Carboplatin + Pembrolizumab (MK3475) in High Intermediate Risk Endometrial Cancer
A Phase Ib Trial of Vaginal Cuff Brachytherapy + Pembrolizumab (MK3475) Followed by 3 Cycles of Dose Dense Paclitaxel/q 21 Day Carboplatin + Pembrolizumab (MK3475) in High Intermediate Risk Endometrial Cancer
Enrollment Status: Recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drugs: Pembrolizumab, Paclitaxel, Carboplatin
Study Phase: Phase 1
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 06, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: May 20, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2025
Intervention Type: Drug
Study Phase: Phase 3
Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 22, 2024
Intervention Type: Diagnostic test, Drug
Study Drug: Standard Chemotherapy
Study Phase: Phase 3
Phase II Trial of Vaginal Cuff Brachytherapy Followed by Adjuvant Chemotherapy With Carboplatin and Dose Dense Paclitaxel in Patients With High-Risk Endometrial Cancer
Phase II Trial of Vaginal Cuff Brachytherapy Followed by Adjuvant Chemotherapy With Carboplatin and Dose Dense Paclitaxel in Patients With High-Risk Endometrial Cancer
Enrollment Status: Completed
Publish Date: March 08, 2024
Intervention Type: Radiation, Drug
Study Drugs: Carboplatin, Paclitaxel
Study Phase: Phase 2
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
View 7 Less Clinical Trials

58 Total Publications

Training, Validating, and Testing Machine Learning Prediction Models for Endometrial Cancer Recurrence.
Training, Validating, and Testing Machine Learning Prediction Models for Endometrial Cancer Recurrence.
Journal: JCO precision oncology
Published: May 05, 2025
Similar Doctors
Expertise in
25
conditions
Dr. Michael J. Callahan
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
25
conditions
Dr. Michael J. Callahan
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

St Vincent Physician Services Hospital And Health Care Center

8402 Harcourt Rd, 
Indianapolis, IN 
 (9.2 mi)
317-338-4372
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Callahan is a Gynecologic Oncologist and an Oncologist in Indianapolis, Indiana. Dr. Callahan is highly rated in 25 conditions, according to our data. His top areas of expertise are Vulvar Cancer, Malignant Mixed Mullerian Tumor, Endometrial Cancer, Oophorectomy, and Salpingo-Oophorectomy. Dr. Callahan is currently accepting new patients.

Expertise in
17
conditions
Dr. Sharon E. Robertson
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
17
conditions
Dr. Sharon E. Robertson
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

University Obstetricians-Gynecologists,inc

550 N University Blvd, 
Indianapolis, IN 
 (0.1 mi)
317-274-8231
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sharon Robertson is a Gynecologic Oncologist and an Oncologist in Indianapolis, Indiana. Dr. Robertson has been practicing medicine for over 16 years is highly rated in 17 conditions, according to our data. Her top areas of expertise are Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Oophorectomy, and Salpingo-Oophorectomy. Dr. Robertson is currently accepting new patients.

Expertise in
17
conditions
Dr. Sarah K. Goodrich
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
17
conditions
Dr. Sarah K. Goodrich
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

St Vincent Physician Services Hospital And Health Care Center

8402 Harcourt Rd, 
Indianapolis, IN 
 (9.2 mi)
317-415-6740
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sarah Goodrich is a Gynecologic Oncologist and an Oncologist in Indianapolis, Indiana. Dr. Goodrich has been practicing medicine for over 17 years is highly rated in 17 conditions, according to our data. Her top areas of expertise are Endometrial Cancer, Endometrial Stromal Sarcoma, Endometritis, and Malignant Mixed Mullerian Tumor. Dr. Goodrich is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Landrum's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 9 Advanced Conditions
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile